Evidence map›Paper›PMID 32576246›Full record

ArticleArthritis research & therapy2020

Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.

Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong-Wook Song, Yi-Hsing Chen, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Tsutomu TakeuchiKeio University School of Medicine, Tokyo, Japan. tsutake@z5.keio.jp.
Yoshiya TanakaUniversity of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
Sakae TanakaUniversity of Tokyo, Tokyo, Japan.
Atsushi KawakamiNagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Yeong-Wook SongSeoul National University, Seoul National University Hospital, Seoul, South Korea.
Yi-Hsing ChenTaichung Veterans General Hospital, Taichung, Taiwan.
Mitsuhiro RokudaAstellas Pharma, Inc., Tokyo, Japan.
Hiroyuki IzutsuAstellas Pharma, Inc., Tokyo, Japan.
Satoshi UshijimaAstellas Pharma, Inc., Tokyo, Japan.
Yuichiro KanekoAstellas Pharma, Inc., Tokyo, Japan.
Yoshihiro NakashimaAstellas Pharma, Inc., Tokyo, Japan.
Teruaki ShiomiAstellas Pharma, Inc., Tokyo, Japan.
Emi YamadaAstellas Pharma, Inc., Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Identifiers

PMID32576246
PMCPMC7310389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.